Related Experiment Videos
The NF-kappaB transcription factor in oncogenesis
1Division of Oncology, Roche Research Center, Hoffmann-La Roche, Inc., Nutley, NJ 07110, USA.
Anticancer Research
|March 1, 1996
Summary
Targeting the RelA subunit of the NF-kappaB complex with antisense oligomers or decoy molecules inhibits cell adhesion, growth, and tumor development, suggesting a therapeutic strategy for cancer.
Area of Science:
- Molecular Biology
- Cancer Research
- Gene Regulation
Background:
- The NF-kappaB transcription factor complex regulates numerous cellular and viral genes.
- NF-kappaB comprises subunits NFKB1 (p50) and RelA (p65), binding to promoters of adhesion molecules, cytokines, and growth factors.
Purpose of the Study:
- To investigate the therapeutic potential of targeting NF-kappaB subunits, specifically RelA, in cancer.
- To evaluate the effects of inhibiting RelA on cell adhesion, growth, and tumor development.
Main Methods:
- Utilized antisense phosphorothioate oligomers targeting RelA and NFKB1.
- Employed stable transfectants expressing dexamethasone-inducible antisense RNA to RelA.
- Applied a "decoy" approach to directly inhibit RelA function.
Main Results:
- Antisense RelA oligomers rapidly inhibited cell adhesion across diverse cell types.
- RelA inhibition demonstrated anti-growth effects on transformed cells in vitro.
- Targeting RelA significantly inhibited tumor growth and induced regression in vivo tumor models.
Conclusions:
- Selective inhibition of the RelA subunit of NF-kappaB offers a promising therapeutic strategy for cancer.
- Transcription factors like RelA can be targeted for selective therapeutic intervention in cancer treatment.